Logo image of ZVSA

ZYVERSA THERAPEUTICS INC (ZVSA) Stock Fundamental Analysis

NASDAQ:ZVSA - Nasdaq - US98987D3008 - Common Stock - Currency: USD

1.22  0 (0%)

After market: 1.19 -0.03 (-2.46%)

Fundamental Rating

2

Overall ZVSA gets a fundamental rating of 2 out of 10. We evaluated ZVSA against 571 industry peers in the Biotechnology industry. ZVSA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ZVSA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ZVSA has reported negative net income.
ZVSA had a negative operating cash flow in the past year.
ZVSA Yearly Net Income VS EBIT VS OCF VS FCFZVSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of ZVSA (-109.81%) is worse than 78.33% of its industry peers.
ZVSA's Return On Equity of -303.53% is on the low side compared to the rest of the industry. ZVSA is outperformed by 75.84% of its industry peers.
Industry RankSector Rank
ROA -109.81%
ROE -303.53%
ROIC N/A
ROA(3y)-406.26%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZVSA Yearly ROA, ROE, ROICZVSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 -500 -1K -1.5K

1.3 Margins

ZVSA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZVSA Yearly Profit, Operating, Gross MarginsZVSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

4

2. Health

2.1 Basic Checks

ZVSA has more shares outstanding than it did 1 year ago.
There is no outstanding debt for ZVSA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ZVSA Yearly Shares OutstandingZVSA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 100K 200K 300K 400K
ZVSA Yearly Total Debt VS Total AssetsZVSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

ZVSA has an Altman-Z score of -10.19. This is a bad value and indicates that ZVSA is not financially healthy and even has some risk of bankruptcy.
ZVSA has a Altman-Z score of -10.19. This is in the lower half of the industry: ZVSA underperforms 73.89% of its industry peers.
ZVSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.19
ROIC/WACCN/A
WACCN/A
ZVSA Yearly LT Debt VS Equity VS FCFZVSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 0.03 indicates that ZVSA may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.03, ZVSA is doing worse than 99.47% of the companies in the same industry.
ZVSA has a Quick Ratio of 0.03. This is a bad value and indicates that ZVSA is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.03, ZVSA is doing worse than 99.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.03
Quick Ratio 0.03
ZVSA Yearly Current Assets VS Current LiabilitesZVSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 96.58% over the past year.
EPS 1Y (TTM)96.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 13.94% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y97.53%
EPS Next 2Y41.36%
EPS Next 3Y25.88%
EPS Next 5Y13.94%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZVSA Yearly Revenue VS EstimatesZVSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 20M 40M 60M 80M
ZVSA Yearly EPS VS EstimatesZVSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 -200 -400 -600

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ZVSA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZVSA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZVSA Price Earnings VS Forward Price EarningsZVSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZVSA Per share dataZVSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100

4.3 Compensation for Growth

A more expensive valuation may be justified as ZVSA's earnings are expected to grow with 25.88% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.36%
EPS Next 3Y25.88%

More info and screens

0

5. Dividend

5.1 Amount

ZVSA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZYVERSA THERAPEUTICS INC

NASDAQ:ZVSA (2/20/2025, 8:00:02 PM)

After market: 1.19 -0.03 (-2.46%)

1.22

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)03-24 2025-03-24/amc
Inst Owners5.87%
Inst Owner Change2548.97%
Ins Owners0.2%
Ins Owner Change0%
Market Cap3.06M
Analysts82.5
Price Target122.4 (9932.79%)
Short Float %5.18%
Short Ratio0.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.54%
Min EPS beat(2)13.46%
Max EPS beat(2)35.61%
EPS beat(4)2
Avg EPS beat(4)-124.42%
Min EPS beat(4)-526.72%
Max EPS beat(4)35.61%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)71.43%
PT rev (3m)71.43%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-11.48%
EPS NY rev (1m)0%
EPS NY rev (3m)-16.71%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.44
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-147.07
EYN/A
EPS(NY)-1.25
Fwd EYN/A
FCF(TTM)-3.63
FCFYN/A
OCF(TTM)-3.63
OCFYN/A
SpS0
BVpS2.8
TBVpS-4.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -109.81%
ROE -303.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-406.26%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.03
Quick Ratio 0.03
Altman-Z -10.19
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.29%
EPS Next Y97.53%
EPS Next 2Y41.36%
EPS Next 3Y25.88%
EPS Next 5Y13.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y46.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-438.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-438.35%
OCF growth 3YN/A
OCF growth 5YN/A